NCT01300546 - Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Migraine

Interventions

DRUG

Sumatriptan/Naproxen Sodium

Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.

DRUG

Naproxen Sodium

Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.

Trial Locations (2)

65807

Clinvest, Springfield

92663

Newport Beach Clinical Research Assoc., Inc., Newport Beach